via University of York
An international team of scientists have discovered a molecule which prevents tumour cells spreading from a primary cancer site to colonise other sites in the body.
The multidisciplinary research team, from the University of York, Leiden University and Technion (Israel Institute of Technology) discovered that the small, sugar-like molecule maintains the integrity of tissue around a tumour during cancer. They have shown the sugar-like molecules markedly reduce cancer spread in mice, paving the way for development towards clinical application.
Metastasis, the spread of cancer cells to distant sites in the body, is what makes cancer so lethal. Metastasis formation depends on the ability of cancer cells to detach from the primary tumour site, and invade through blood vessel walls and tissue barriers to reach secondary sites of growth. This metastatic invasion process requires biological molecules called enzymes, which digest proteins and sugars in the space around cells, enabling cancer cells to pass through the subsequent gaps.
One abundant class of sugar that surrounds cells are the heparan sulfates, which are long chain-like molecules that help stabilise the integrity of the extracellular space. Heparan sulfate sugars are digested by an enzyme called heparanase, which acts to chop up the ‘chains’ and thereby weaken the space around cells.
Metastatic cancer cells produce large amounts of heparanase enzyme, which helps them to spread around the body. Inhibiting heparanase is therefore a major target for anti-cancer therapy.
The researchers developed and tested a new sugar-like molecular that reacts with the enzyme heparanase, whose 3-D structure was first solved by the York group. Once the new molecule is bound, the heparanase enzyme is unable to bind or cut heparin sugar chains around cells. In this way, the tissue around cells remains firm and inaccessible to dislodged cells.
At York, Professor Gideon Davies and Dr Liang Wu from the Department of Chemistry showed how the enzyme inhibitor inhibits heparanase. The research team is now looking at how the molecule can be further improved.
Professor Davies said: “It has been brilliant to see the work develop from fundamental studies of enzyme structure and function and evolve into small molecules with potent anti-cancer activities. It is really exciting”
Researchers at Technion studied the new molecule in mouse models of lung cancer, breast cancer and blood cancer. While it is still too early to determine whether the new molecule will reach clinical application, the results are promising and the institutes involved have already applied for a patent on the molecule.
Lead author of the study Professor Hermen Overkleeft from Leiden University said: “Now we have to find out whether the compound is stable, safe for the human body, ends up in the right place in sufficient quantities, and so on. That takes a couple of years, it may come to nothing and someone has to be willing to take that financial risk.
“Our molecule is one of the few agents that can inhibit heparanase tightly and specifically. Medicine has a preference for small, simple molecules like this.”
Original Article: Chemists create molecule that prevents tumour cells from spreading
The Latest Updates from Bing News
Go deeper with Bing News on:
- Nanodiamonds can block tumor metastasis in mice, study shows
Nanodiamonds are 2–8 nm carbon nanoparticles, which can be easily functionalized with various chemical groups like carboxylic groups or drugs. Previous research has shown that actively dividing cells ...
- SUO 2023: PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients
Approximately 11% of prostate cancer patients with biochemical failure undergoing an 18 F-DCFPyL-PET/CT scan have mesorectal lymph node metastasis, with presence of pT3b disease associated with a 4.31 ...
- Newly discovered spine stem cells help explain cancer metastasis in bone
Researchers found a particular type of stem cell that helps form the spine. The cell secretes a protein that seems to attract cancer, which could help explain why certain types of cancer spread more ...
- Exploring cSCC: Transcriptomic Analysis Unveils Multigene Prognostic Signature Linked to Metastasis
The following is a summary of "Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multigene prognostic signature associated with metastasis," published in the December 2023 issue ...
- Screening Associated With Overall Survival After Metachronous Metastasis in CRC
Patients with colorectal cancer (CRC) who had diagnosed metachronous metastasis had longer overall survival when the primary tumor was detected through screening. Longer overall survival (OS) was ...
Go deeper with Bing News on:
- Duloxetine: A Balanced and Selective Norepinephrine and Serotonin-Reuptake Inhibitor
For diabetic peripheral neuropathic pain, the recommended dosage is 60 mg per day, although dosages of up to 120 mg daily have been studied.  Higher dosages do not have proven benefit and may ...
- Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors
 Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...
- Targeting cancer with small molecule kinase inhibitors
Small-molecule kinase inhibitors are being intensively pursued as new anticancer therapeutics. To date, approximately 80 inhibitors have been advanced to some stage of clinical evaluation.
- 10 Best Rust Converters & Inhibitors of 2023
A list of the best rust converters and inhibitors in the market today. Read our review and buyers guide to find everything you need to know about these products. Mechanic Base is supported by its ...
- What Are ACE Inhibitors?
Guidelines for treating high blood pressure recommend angiotensin-converting enzyme inhibitors — commonly called ACE inhibitors — as one of the first lines of treatment for high blood pressure.